AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026.
Financial Highlights & Recent Developments
- Research and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines.
- Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.
“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while continuing to invest selectively in the highest-return areas of the business. As a result, we are better positioned to operate efficiently in a dynamic macro environment. At the same time, our sales team is advancing a healthy sales pipeline supported by strong lead generation and ongoing customer engagement across key markets. Our deployments to date support these efforts with real-world demonstration of our solution capabilities and compelling data affirming the unique benefits of mass spectrometry technology in industrial, safety and trace detection applications. Looking ahead, we will continue to balance rigorous expense control with strategic investments to help convert pipeline opportunities into revenue growth”, said Thomas B. Pickens, III, Astrotech’s Chairman and Chief Executive Officer.
About Astrotech Corporation
Astrotech Corporation (Nasdaq: ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening.
- AgLAB designs process analyzers tailored to the processing of agriculture products.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
- EN-SCAN, Inc. delivers portable, ruggedized environmental GC-MS for on-site testing of air, water and soil.
Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contact:
Scott Bartley
Interim Chief Financial Officer, Astrotech Corporation
(512) 485-9530
Investor Contact:
Matt Kreps
Managing Director, Darrow Associates
(214) 597-8200 [email protected]
Financial tables follow
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
(Unaudited) Three Months Ended Nine Months Ended March 31, March 31, 2026 2025 2026 2025 Revenue $343 $534 $787 $829 Cost of revenue 276 297 525 428 Gross profit 67 237 262 401 Operating expenses: Selling, general and administrative 2,085 2,115 5,941 5,842 Research and development 1,435 1,989 5,211 6,375 Total operating expenses 3,520 4,104 11,152 12,217 Loss from operations (3,453) (3,867) (10,890) (11,816)Other income and expense, net (315) 234 (271) 896 Loss from operations before income taxes (3,768) (3,633) (11,161) (10,920)Net loss $(3,768) $(3,633) $(11,161) $(10,920)Weighted average common shares outstanding: Basic and diluted 1,677 1,665 1,676 1,663 Basic and diluted net loss per common share: Net loss per common share $(2.25) $(2.18) $(6.66) $(6.57)Other comprehensive loss, net of tax: Net loss $(3,768) $(3,633) $(11,161) $(10,920)Available-for-sale securities: Net unrealized gain (loss) 159 139 476 236 Total comprehensive loss $(3,609) $(3,494) $(10,685) $(10,684)
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data) March 31, June 30, 2026 2025 (Unaudited) (Note) Assets Current assets Cash and cash equivalents $2,679 $3,100 Short-term investments 3,903 15,108 Accounts receivable 504 485 Inventory, net: Raw materials 3,019 2,194 Work-in-process 531 425 Finished goods 310 310 Prepaid expenses and other current assets 383 353 Total current assets 11,329 21,975 Property and equipment, net 2,573 2,395 Intangible asset, net 50 48 Operating lease right-of-use assets, net 1,906 2,225 Other assets, net 315 346 Total assets $16,173 $26,989 Liabilities and stockholders’ equity Current liabilities Accounts payable $234 $1,066 Payroll related accruals 461 529 Accrued expenses and other liabilities 865 451 Lease liabilities, current 275 405 Total current liabilities 1,835 2,451 Accrued expenses and other liabilities, net of current portion 79 164 Lease liabilities, net of current portion 2,104 2,274 Total liabilities 4,018 4,889 Commitments and contingencies (Note 14) Stockholders’ equity Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2026, and June 30, 2025 — — Common stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2026, and June 30, 2025, respectively; 1,769,269 shares issued at March 31, 2026, and June 30, 2025 respectively; 1,758,953 shares outstanding at March 31, 2026, and June 30, 2025. 190,643 190,643 Treasury shares, 10,316 at March 31, 2026, and June 30, 2025, respectively (119) (119)Additional paid-in capital 84,050 83,310 Accumulated deficit (262,030) (250,870)Accumulated other comprehensive loss (389) (864)Total stockholders’ equity 12,155 22,100 Total liabilities and stockholders’ equity $16,173 $26,989
Note: The balance sheet at June 30, 2025 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.